It can't be completely invalid, not since the FDA would also be making the exact same comparisons when considering Veyonda for approval as an add-on treatment, along with the data generated by NOX.
Ann: New Independent Trial Data Supports Potential of Veyonda, page-7
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $11.03K | 105.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 418372 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 102513 | 3 |
View Market Depth
| Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |